Thermo Fisher Scientific, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., QIAGEN, BGI, Agilent Technologies, Guardant Health, Biocept, Inc., Myriad Genetics, Inc., and eviCore healthcare among others, are some key players operating the in the Oncology Sequencing Market.

Brooklyn, New York, Aug. 24, 2022 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Global Oncology Sequencing Market is projected to grow at a CAGR of 13.5% from 2022 to 2027.

The growing popularity of personalized therapies, plummeting sequencing prices, and improved genomic data management solutions are some key factors that are driving market revenue.

Browse 151 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC on “Global Oncology Sequencing Market - Forecast to 2027’’

Key Market Insights

• As per the technology outlook, the whole-genome sequencing segment was the highest revenue-generating segment in the 2021 oncology sequencing market
• Based on the product outlook, the consumables segment is estimated to dominate the 2021 global market in terms of revenue generation
• By application segment, the research application has dominated the market owing to the high penetration of NGS in research settings
• Based on indication, breast cancer and lunch cancer are recognized as the two key shareholder segments in the year 2021
• Among the end-users, government and academic research institutes are estimated to capture maximum revenue share in the year 2021
• North America (the United States, Canada, and Mexico) market is estimated to account for a major revenue share in the global oncology sequencing market from 2022 to 2027
• The Asia Pacific region is expected to serve as the fastest revenue-generating market during the forecast period
• Thermo Fisher Scientific, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., QIAGEN, BGI, Agilent Technologies, Guardant Health, Biocept, Inc., Myriad Genetics, Inc., and eviCore healthcare among others, are some key players in the oncology sequencing market

Request a Sample Copy of the Report @ https://www.globalmarketestimates.com/market-report/oncology-sequencing-market-3892

Technology Outlook (Revenue, USD Million, 2022-2027)

• Whole-Genome Sequencing
• Exome Sequencing
• Targeted Sequencing
• RNA Sequencing

Application Outlook (Revenue, USD Million, 2022-2027)

• Clinical
• Research

Product Outlook (Revenue, USD Million, 2022-2027)

• Instruments & Platforms
• Reagents & Other Consumables

End-use Outlook (Revenue, USD Million, 2022-2027)

• Pharmaceutical & Biotechnology Company
• Academic & Government Research Institutes
• Others
  

Indication Outlook (Revenue, USD Million, 2022-2027)

• Breast Cancer
• Ovarian Cancer
• Prostate Cancer
• Lung Cancer
• Colorectal Cancer
• Melanoma
• Cervical Cancer
• Others

Regional Outlook (Revenue, USD Million, 2022-2027)

North America        

• The U.S.
• Canada
• Mexico
  

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• Rest of APAC
  

Central & South America

• Brazil
• Rest of CSA

Middle East & Africa

• Saudi Arabia
• South Africa
• Rest of MEA
  
  

Contact: Yash Jain

Email address: yash.jain@globalmarketestimates.com

Phone Number: +16026667238

Contact: Yash Jain

Email address: yash.jain@globalmarketestimates.com

Phone Number: +16026667238

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.